Literature DB >> 11994982

Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.

Brynjar Vidarsson1, Deane F Mosher, M Shahriar Salamat, Helgi J Isaksson, Pall T Onundarson.   

Abstract

Fludarabine is becoming the initial therapy for low-grade lymphoproliferative malignancies, such as CLL and follicular lymphoma. Fludarabine is highly immunosuppressive in addition to being myelosuppressive and has been associated with neurotoxicity. Progressive multifocal leukoencephalopathy (PML) is an infection with JC virus of the white matter of the central nervous system seen mostly in immunosuppressed patients. We describe two patients treated with fludarabine who developed PML. Immunolabeling was positive for JCV in both patients, but PCR was repeatedly negative in one of them. We suggest that fludarabine may increase the risk of PML in patients with lymphoproliferative diseases. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11994982     DOI： 10.1002/ajh.10085

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  9 in total

Review 1.  Cancer-treatment-induced neurotoxicity--focus on newer treatments.

Authors:  Jacqueline B Stone; Lisa M DeAngelis
Journal:  Nat Rev Clin Oncol       Date:  2015-09-22       Impact factor: 66.675

Review 2.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 3.  Neurologic complications of chemotherapy for children with cancer.

Authors:  Alyssa T Reddy; Kerry Witek
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

Review 4.  Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.

Authors:  Hiroki Yokoyama; Takashi Watanabe; Dai Maruyama; Sung-Won Kim; Yukio Kobayashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2008-10-15       Impact factor: 2.490

5.  Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients.

Authors:  Mary K Grabowski; Raphael P Viscidi; Joseph B Margolick; Lisa P Jacobson; Keerti V Shah
Journal:  J Med Virol       Date:  2009-07       Impact factor: 2.327

6.  High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

Authors:  J R Long-Boyle; K G Green; C G Brunstein; Q Cao; J Rogosheske; D J Weisdorf; J S Miller; J E Wagner; P B McGlave; P A Jacobson
Journal:  Bone Marrow Transplant       Date:  2010-04-12       Impact factor: 5.483

7.  Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report.

Authors:  Claudio Annaloro; Antonella Costa; Nicola S Fracchiolla; Gabriella Mometto; Silvia Artuso; Giorgia Saporiti; Elena Tagliaferri; Federica Grifoni; Francesco Onida; Agostino Cortelezzi
Journal:  Clin Case Rep       Date:  2015-06-11

8.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

Review 9.  Central Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell Transplantation.

Authors:  Duccio Maria Cordelli; Riccardo Masetti; Daniele Zama; Francesco Toni; Ilaria Castelli; Emilia Ricci; Emilio Franzoni; Andrea Pession
Journal:  Front Pediatr       Date:  2017-05-15       Impact factor: 3.418
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.